Fundamental Analysis of Unicycive Therapeutics Inc - Growth / Value Index
UNCY - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Book Value in last 3 years is trending down
Book value is negative
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -0.688 | -769.20 | -104730.54 % | |
| Price to Book | -17.28 | -5669.36 | 80.06 % | -1.26 |
| Price to Sales | -95.42 | 31991.99 | 229514 % | |
| Enterprise Value to EBITDA Multiple | -0.933 | -777.45 | -104877.52 % |
UNCY - Profitability Highlights
Profitability Analysis
Strong Return On Capital Employed of 740.54
Company Earning excess return
During the past twelve months, the company has given a strong Net Margin of 13877.12%
All key Trailing Twelve Months Margin growing by 15 %
Tsr Profitability Index - Poor Score of 20.54
Piotroski F Score - Very Poor Value of 1.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
EPS decline for last four quarters
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 0 | 0 | 0 % | 0 |
| Return On Asset | -138.16 | -197.83 | 99.97 % | -40.02 |
| Net Profit Margin | 13877.12 | -4159.11 | -119.03 % | 0 |
| Operating Profit Margin | 9511.81 | -2931.26 | -54.42 % | 0 |
| EBITDA Margin | 9376.75 | -4113.19 | -118.64 % | 0 |
Highlights
| Market Cap | 33093.81 K |
| Enterprise Value | 23719.81 K |
| Price/Book TTM | -17.28 |
| Outstanding Share | 37606.60 K |
| Float/ Outstanding Share | 39.30% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 1.00 |
| Altman Z Score | -12.09 |
| Sloan Ratio | -0.574 |
| Peter Lynch Fair Value | 0 |
UNCY - Growth Highlights
Growth Analysis
YoY Net Margin Jump by 119.03%
Tsr Growth Index - Very Poor Score of 5.00
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | -271000.00 | 29.02 % | 100.00 % |
| Gross Profit | -523000.00 | 29.02 % | 246.34 % |
| EBITDA | -25411.00 K | 55.18 % | 43.16 % |
| Net Profit | -37607.00 K | 55.47 % | 168.83 % |
| EPS | -1.28 | 99.90 % | NA |
UNCY - Stability Highlights
Stability Analysis
Tsr Stability Index - Very Poor Score of 5.00
Altman Z Score of -11.89 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of -424.36
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | -0.086 | 74.19 % | -0.0140 |
| Cash Ratio | 0.553 | 299.33 % | |
| Quick Ratio | 0 | 0 % | 1.71 |
| Shareholders Equity | -26.84 | -62.31 % | |
| Debt to EBITDA | -0.0118 | -135846.69 % |
Historical Valuation Ratios of Unicycive Therapeutics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Unicycive Therapeutics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Unicycive Therapeutics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Unicycive Therapeutics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)